Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Regeneron reported Q4 2024 earnings today - revenues were up 10% YoY to $3.79bn. Full-year revenues were up 8% to $14.2bn. Q4 GAAP EPS at $8.06, and $38 adj. full-year. The company declared its ...

Leonard Schleifer; Co-Chairman of the Board, President, Chief Executive Officer, Founder; Regeneron Pharmaceuticals Inc George Yancopoulos; Co-Chairman of the Board, President, Chief Scientific ...

Meme stocks like AMC Entertainment and GameStop get their price spikes from exceptional buying interest. GameStop jumped on ...

Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The ...

It notched a convincing beat on net income. The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Although non-GAAP (adjusted) net income didn't rise as ...

Regeneron has started 2025 with an increase in defensive capital allocation - initiation of a dividend and an expanded share buyback program. Increased competitive pressure on the Eylea franchise ...

News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the second trading day of the week. The company posted its fourth-quarter ...

Anti-inflammatory Dupixent's sales are up 15%, and a midstage trial of treatment for muscle loss caused by obesity drugs is fully enrolled Regeneron Pharmaceuticals Inc.'s stock rose 4.9% Tuesday ...

Dow Jones home improvement giant Home Depot is approaching a new buy point ahead of fourth quarter earnings results.

Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc. have announced a strategic research collaboration within the field of conditionally activated bispecific therapeutics for the ...